Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors

Transplantation

Volumn 68, Issue 7, 1999, Pages 1058-1061

  Dodson, S Forrest ^a,b   Bonham, C Andrew ^a   Geller, David A ^a   Cacciarelli, Thomas V ^a   Rakela, Jorge ^a   Fung, John J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; LAMIVUDINE;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS B; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; ORGAN DONOR; PRIORITY JOURNAL;

HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033569838     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199910150-00028     Document Type: Article

References (13)

1. Dodson SF, Issa S, Araya V, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64: 1582-1584.
2. Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113: 1668-1674.
3. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HbcAB(+), HBIgM(-) organ donors. Transplantation 1995; 59: 230-234.
4. Lutwick LI, Sywassink JM, Corry RJ, Shorey JW. The transmission of hepatitis B by renal transplantation. Clin. Nephrol. 1983; 19: 317-319.
5. Douglas DD, Rakela J, Wright TL, Krom RAF, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transplantation and Surgery 1997; 3(2): 105-111.
6. Burbach GJ, Bienzle U, Neuhaus P, et al. Intravenous or intra-muscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation. Transplantation 1997; 63: 478-480.
7. Sawyer RG, McGory RW, Gaffey MJ McCullough CC, Shephard BL, Houlgrave W, Ryan TS, Kuhns M, McNamara A, Caldwell SH, Abdulkareem A, Pruett TL. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Annals of Surgery 1998; 6: 841-850.
8. Lowell JA, Burgess S, Shenoy S Curci JA, Peters M, Howard TK. Mercury poisoning associated with high-dose hepatitis-B immune globulin administration after liver transplantation for chronic hepatitis B. Liver Transplantation and Surgery 1996; 2(6): 475-478.
9. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-713.
10. Turner DPJ, Zucherman M, Alexander GJM, Waite J, Wreghitt T. Risk of inappropriate exclusion of organ donors by introduction of hepatitis B core antibody testing. Transplantation 1997; 63: 775-777.
11. Brechot C, Degos F, Lugassy C, et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests fro hepatitis B surface antigen. N Engl J Med 1985; 312: 270-6.
12. Fong T, Govindarajan S, Valinluck B, et al. Status of hepatitis B virus DNA in alcoholic liver disease: a study of a large urban population in the United States. Hepatology 1988; 8: 1602-4.
13. Yokosuka O, Omata M, Imazeki F, et al. Hepatitis B virus RNA transcripts and DNA in chronic liver disease. N Engl J Med 1986; 315: 1187-92.